Lu Wang

Lu Wang

Auto-generated profile, based on publicly available information

Lu Wang

Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
MCMatthew D. Campbell
Matthew D. Campbell
JDJicheng Duan
Jicheng Duan
ASAshton T. Samuelson
Ashton T. Samuelson
MGMatthew J. Gaffrey
Matthew J. Gaffrey
GMGennifer E. Merrihew
Gennifer E. Merrihew
David J. MarcinekDavid J. Marcinek
David J. Marcinek

20 December 2018 in JCI Insight
Verified
Journal Article
Open access
PDF file
EWElijah J. Weber
Elijah J. Weber
KLKevin A. Lidberg
Kevin A. Lidberg
LWLu Wang
Lu Wang
TBTheo K. Bammler
Theo K. Bammler
JMJames W. MacDonald
James W. MacDonald
EKEdward Kelly
Edward Kelly
Drug-induced kidney injury, largely caused by proximal tubular intoxicants, limits development and clinical use of new and approved drugs. Assessing preclinical nephrotoxicity relies on animal models that are frequently insensitive; thus, potentially novel techniques — including human microphysiological systems, or “organs on chips” — are proposed to accelerate drug development and predict safety. Polymyxins are potent antibiotics against multidrug-resistant microorganisms; however, clinical use remains restricted because of high risk of nephrotoxicity and limited understanding of toxicological mechanisms. To mitigate risks, structural analogs of polymyxins (NAB739 and NAB741) are currently in clinical development. Using a microphysiological system to model human kidney proximal tubule, we exposed cells to polymyxin B (PMB) and observed significant increases of injury signals, including kidney injury molecule-1 KIM-1and a panel of injury-associated miRNAs (each P < 0.001). Surprisingly, transcriptional profiling identified cholesterol biosynthesis as the primary cellular pathway induced by PMB ( P = 1.22 ×10 –16 ), and effluent cholesterol concentrations were significantly increased after exposure ( P < 0.01). Additionally, we observed no upregulation of the nuclear factor (erythroid derived-2)–like 2 pathway, despite this being a common pathway upregulated in response to proximal tubule toxicants. In contrast with PMB exposure, minimal changes in gene expression, injury biomarkers, and cholesterol concentrations were observed in response to NAB739 and NAB741. Our findings demonstrate the preclinical safety of NAB739 and NAB741 and reveal cholesterol biosynthesis as a potentially novel pathway for PMB-induced injury. To our knowledge, this is the first demonstration of a human-on-chip platform used for simultaneous safety testing of new chemical entities and defining unique toxicological pathway responses of an FDA-approved molecule.

Verified
Journal Article
Open access
PDF file
KEKaris A. Ederer
Karis A. Ederer
KJKelly Jin
Kelly Jin
SBSarah Bouslog
Sarah Bouslog
LWLu Wang
Lu Wang
GGGreg Gorman
Greg Gorman
MLMaria De Luca
Maria De Luca
The angiotensin-converting enzyme (ACE) is a peptidase that is involved in the synthesis of Angiotensin II, the bioactive component of the renin-angiotensin system. A growing body of literature argues for a beneficial impact of ACE inhibitors (ACEi) on age-associated metabolic disorders, mediated by cellular changes in reactive oxygen species (ROS) that improve mitochondrial function. Yet, our understanding of the relationship between ACEi therapy and metabolic parameters is limited. Here, we used three genetically diverse strains of Drosophila melanogaster to show that Lisinopril treatment reduces thoracic ROS levels and mitochondrial respiration in young flies, and increases mitochondrial content in middle-aged flies. Using untargeted metabolomics analysis, we also showed that Lisinopril perturbs the thoracic metabolic network structure by affecting metabolic pathways involved in glycogen degradation, glycolysis, and mevalonate metabolism. The Lisinopril-induced effects on mitochondrial and metabolic parameters, however, are genotype-specific and likely reflect the drug’s impact on nutrient-dependent fitness traits. Accordingly, we found that Lisinopril negatively affects survival under nutrient starvation, an effect that can be blunted by genotype and age in a manner that partially mirrors the drug-induced changes in mitochondrial respiration. In conclusion, our results provide novel and important insights into the role of ACEi in cellular metabolism.

2 January 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
YCYing Ann Chiao
Ying Ann Chiao
HZHuiliang Zhang
Huiliang Zhang
MSMariya Sweetwyne
Mariya Sweetwyne
JWJeremy Whitson
Jeremy Whitson
YTYing Sonia Ting
Ying Sonia Ting
PRPeter Rabinovitch
Peter Rabinovitch
Diastolic dysfunction is a prominent feature of cardiac aging in both mice and humans. We show here that 8-week treatment of old mice with the mitochondrial targeted peptide SS-31 (elamipretide) can substantially reverse this deficit. SS-31 normalized the increase in proton leak and reduced mitochondrial ROS in cardiomyocytes from old mice, accompanied by reduced protein oxidation and a shift towards a more reduced protein thiol redox state in old hearts. Improved diastolic function was concordant with increased phosphorylation of cMyBP-C Ser282 but was independent of titin isoform shift. Late-life viral expression of mitochondrial-targeted catalase (mCAT) produced similar functional benefits in old mice and SS-31 did not improve cardiac function of old mCAT mice, implicating normalizing mitochondrial oxidative stress as an overlapping mechanism. These results demonstrate that pre-existing cardiac aging phenotypes can be reversed by targeting mitochondrial dysfunction and implicate mitochondrial energetics and redox signaling as therapeutic targets for cardiac aging.

7 July 2021 in GeroScience
Verified
Journal Article
Closed access
PDF file
MKMatt Kaeberlein
Matt Kaeberlein
ABAlessandro Bitto
Alessandro Bitto
MDMaitreya J. Dunham
Maitreya J. Dunham
WLWarren Carl Ladiges
Warren Carl Ladiges
SLSu-In Lee
Su-In Lee
Jessica YoungJessica Young
Jessica Young